Vectory Doses First Patient in Phase 1/2 ALS Trial
Amsterdam, Netherlands | February 9 2026 — Vectory Therapeutics has announced that the first participant has been dosed in...
RNA therapeutics
Advertisement
Junevity Secures $20M to Advance siRNA Cell-Reprogramming Platform
SAN FRANCISCO, December 3, 2025 — Junevity today announced the expansion of its seed funding round to $20 million...
Phio to Present INTASYL siRNA Advances at ATUSA 2025
Dateline IntroductionNovember 17, 2025 — Marlborough, Massachusetts — Phio Pharmaceuticals Corp., a clinical-stage biopharmaceutical company advancing RNA-based immuno-oncology therapeutics,...
Phio Pharmaceuticals Advances siRNA Immunotherapy in Skin Cancer with INTASYL PH-762
Dateline — King of Prussia, Pennsylvania, November 7, 2025:Phio Pharmaceuticals Corp. (NASDAQ: PHIO) has announced new clinical data from...
Wave Life Sciences Advances RNA Innovation Ahead of Q3 2025 Results
CAMBRIDGE, Mass., November 4, 2025 — Wave Life Sciences Ltd. (NASDAQ: WVE), a clinical-stage biotechnology company pioneering the use...
Advertisements
Vir Completes Phase 3 Enrollment for Hepatitis Delta Trial
San Francisco, California – November 3, 2025 Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on harnessing...
Phio Pharmaceuticals Strengthens Governance with New Lead Director
King of Prussia, Pennsylvania – October 31, 2025 — Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biopharmaceutical company developing...
Wave Life Sciences’ RNA Breakthrough Targets Obesity and Liver Disorders
BOSTON, October 29, 2025 — Wave Life Sciences Ltd. (NASDAQ: WVE), a clinical-stage biotechnology leader in RNA medicines, has...
Novartis Expands RNA Therapeutics Portfolio with Avidity Acquisition
Basel, Switzerland – October 26, 2025: Novartis AG announced its agreement to acquire Avidity Biosciences, a U.S. biotechnology company...
TransCode Reports Positive Phase 1a Results for TTX-MC138 in Metastatic Cancer
BOSTON, Massachusetts, October 14, 2025 — TransCode Therapeutics, Inc. (NASDAQ: RNAZ) today announced encouraging preliminary data from its completed...
Advertisement
